<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941394</url>
  </required_header>
  <id_info>
    <org_study_id>NRCH-MSC</org_study_id>
    <nct_id>NCT01941394</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation</brief_title>
  <official_title>Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant (BMT)
      for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis and
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infusion of mesenchymal stem cells at day of recovery after BMT for patients with AL, AA and
      MM for acute GVHD prophylaxis and treatment. Infusion at dose 1 cells mln/kg at day of white
      blood cells recovery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GVHD</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Graft-versus-host Disease</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>With MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion of Mesenchymal stem cells at dose 1 mln cells per kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without MSC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without MSC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Mesenchymal stem cells infusion</description>
    <arm_group_label>With MSC</arm_group_label>
    <other_name>Mesenchymal stem cells infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allogenic BMT from related or unrelated donor

        Exclusion Criteria:

          -  Severe infection

          -  Relapse

          -  admission to ICU

          -  refusal of research

          -  patients with graft failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
    <phone>+79161252623</phone>
    <email>elenap@blood.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Larisa Kuzmina, MD PhD</last_name>
    <phone>+79161487131</phone>
    <email>kuzlara@rambler.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BMT department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
      <phone>+79161487131</phone>
      <email>kuzlara@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Parovichnikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV, Shipounova IN, Zhironkina OA, Bigildeev AE, Svinareva DA, Drize NJ, Savchenko VG. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int. 2012;2012:968213. doi: 10.1155/2012/968213. Epub 2011 Dec 25.</citation>
    <PMID>22242033</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>Head of BMT department</investigator_title>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>Relapse</keyword>
  <keyword>Overall Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

